NYSE:RCUS Arcus Biosciences (RCUS) Stock Price, News & Analysis $17.80 -1.00 (-5.34%) Closing price 03:59 PM EasternExtended Trading$18.06 +0.26 (+1.48%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arcus Biosciences Stock (NYSE:RCUS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcus Biosciences alerts:Sign Up Key Stats Today's Range$17.76▼$18.6550-Day Range$17.67▼$30.0352-Week Range$17.43▼$31.74Volume1.10 million shsAverage Volume1.42 million shsMarket Capitalization$2.56 billionP/E RatioN/ADividend YieldN/APrice Target$39.36Consensus RatingModerate Buy Company Overview Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2015 and headquartered in Hayward, California, the company researches therapies that target immune pathways and other processes involved in tumor growth. Its pipeline consists of investigational medicines, including antibody and small-molecule candidates designed to be used alone or in combination. Arcus’s research has focused on areas such as checkpoint inhibition and the adenosine pathway; its candidates are under clinical development and are not established treatments. Arcus works with Gilead Sciences on the development of oncology medicines, extending its work through a major biopharmaceutical collaboration. The company’s research and development operations are based in the United States, with its collaboration supporting development and potential commercialization across broader markets.AI Generated. May Contain Errors. Read More Arcus Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreRCUS MarketRank™: 2.98630136986 of 5 starsArcus Biosciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 316th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingArcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 12 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArcus Biosciences has a consensus price target of $39.36, representing about 121.2% upside from its current price of $17.80.Amount of Analyst CoverageArcus Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcus Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arcus Biosciences are expected to grow in the coming year, from ($3.47) to ($3.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -4.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 7.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.90% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 3.56, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcus Biosciences has recently increased by 6.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment0.19 News SentimentArcus Biosciences has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Arcus Biosciences this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for RCUS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $84,810.00 in company stock.Percentage Held by Insiders7.60% of the stock of Arcus Biosciences is held by insiders.Percentage Held by Institutions92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcus Biosciences' insider trading history. Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RCUS Stock News HeadlinesArcus Biosciences (NYSE:RCUS) Price Target Cut to $45.00 by Analysts at WedbushNovember 6, 2026 | americanbankingnews.comPrecision BioSciences Prices $125 Mln Underwritten Offering To Fund Gene-Editing ProgramsNovember 6, 2026 | rttnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 12 at 1:00 AM | Base Camp Trading (Ad)Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNovember 5, 2026 | marketscreener.comMPrecision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD StudyNovember 5, 2026 | marketscreener.comMPrecision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral CureNovember 5, 2026 | tmcnet.comArcus Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMArcus Biosciences, Inc. (NYSE:RCUS) Stock Has Average Target Price of $39.64 According to AnalystsNovember 5, 2026 | americanbankingnews.comSee More Headlines RCUS Stock Analysis - Frequently Asked Questions How have RCUS shares performed this year? Arcus Biosciences' stock was trading at $23.90 at the beginning of the year. Since then, RCUS shares have decreased by 25.5% and is now trading at $17.7960. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) released its quarterly earnings results on Wednesday, November, 4th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.11. The firm's revenue was down 65.4% on a year-over-year basis. When did Arcus Biosciences IPO? Arcus Biosciences (RCUS) raised $112 million in an IPO on Thursday, March 15th 2018. The company issued 8,000,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO. Who are Arcus Biosciences' major shareholders? Arcus Biosciences' top institutional shareholders include State Street Corp (3.87%), Fisher Asset Management LLC (1.51%), Aberdeen Group plc (0.83%) and Candriam S.C.A. (0.42%). Insiders that own company stock include Gilead Sciences, Inc, Terry J Rosen, Juan C Jaen, Jennifer Jarrett, Carolyn C Tang, Robert C Goeltz II, Richard Markus, Alexander Azoy and Yasunori Kaneko. View institutional ownership trends. How do I buy shares of Arcus Biosciences? Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), Viking Therapeutics (VKTX) and Micron Technology (MU). Company Calendar Last Earnings11/04/2026Today11/12/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, RCUS's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:RCUS CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees601Year Founded2015Price Target and Rating Average Price Target for Arcus Biosciences$39.36 High Price Target$50.00 Low Price Target$23.00 Potential Upside/Downside+121.2%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($3.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$353 million Net Margins-453.00% Pretax Margin-453.00% Return on Equity-91.65% Return on Assets-46.72% Debt Debt-to-Equity Ratio0.28 Current Ratio3.34 Quick Ratio3.34 Sales & Book Value Annual Sales$247 million Price / Sales10.37 Cash FlowN/A Price / Cash FlowN/A Book Value$2.49 per share Price / Book7.15Miscellaneous Outstanding Shares143,990,000Free Float133,048,000Market Cap$2.56 billion OptionableOptionable Beta1.04 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSE:RCUS) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon wants to move AI off the planet. Amazon isn't ready.What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCUS Stock Alerts